Latest News
CEO Foran discusses margin gains amid macro headwinds and regulatory pressures.
Via The Motley Fool · September 11, 2026
Tariff recoveries and cost cuts drive profitability amid weak housing demand and lower sales.
Via The Motley Fool · September 11, 2026
EBITDA losses narrowed 17% despite revenue decline as cost cuts accelerated.
Via The Motley Fool · September 11, 2026
Exxon is leaning into growth, but a significant portion of that growth will come from one place.
Via The Motley Fool · September 11, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and
Via MarketBeat · September 11, 2026
The auto resale platform received an enticing buyout offer.
Via The Motley Fool · September 11, 2026
The transaction was valued at $1.6 million.
Via The Motley Fool · September 11, 2026
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.
Via The Motley Fool · September 11, 2026
TD Bank (TSX:TD) stock is a dividend hero that I wouldn't sell after the recent run.
Via The Motley Fool · September 11, 2026
Nowgoal mobi vươn lên thành nền tảng cung cấp dữ liệu tỷ số bóng đá trực tuyến uy tín và phổ biến rộng rãi tại Việt Nam. Chúng tôi mang đến hệ thống thông
Via Talk Markets · September 11, 2026
AI agents from OpenAI attacked a software service called RubyGems in May, months before the hack on Hugging Face.
Via Benzinga · September 11, 2026
Apple (NASDAQ:AAPL) has a small dividend, but it's growing steadily. After a strong device showcase, perhaps the best spot for the shares is your TFSA.
Via The Motley Fool · September 11, 2026
CT REIT (TSX:CRT.UN) might be the retail REIT to buy as shares plunge and yields swell.
Via The Motley Fool · September 11, 2026
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.
Speaking at the Cantor Healthcare Conference, President and Chief Executive
Via MarketBeat · September 11, 2026
CN Rail (TSX:CNR) may be the steadiest compounder on the entire Canadian stock market.
Via The Motley Fool · September 11, 2026
This transaction appears to be routine.
Via The Motley Fool · September 11, 2026
The tech giant has rebounded from its recent slump, but there may not be much near-term upside left.
Via The Motley Fool · September 11, 2026
This stock is down 15% from the recent highs and now offers an attractive dividend yield.
Via The Motley Fool · September 11, 2026
Snowflake surprised investors by delivering stronger-than-expected revenue growth.
Via The Motley Fool · September 11, 2026
Sales could accelerate for Qualcomm as early as its next fiscal year.
Via The Motley Fool · September 11, 2026
Meta Platforms has invested aggressively in artificial intelligence.
Via The Motley Fool · September 11, 2026
The foldable iPhone was announced to rave reviews.
Via The Motley Fool · September 11, 2026
Its customers appreciate the value as sales continue to increase.
Via The Motley Fool · September 11, 2026
Pinterest (NYSE:PINS) CEO Bill Ready said the company has evolved from a visual discovery and browsing platform into what he described as an AI-driven shopping assistant serving more than 640 million users. Speaking at a conference fireside chat, Ready said the company’s efforts to make the platform
Via MarketBeat · September 11, 2026
The management team has not yet found an effective strategy to counter increasing trade barriers in the U.S.
Via The Motley Fool · September 11, 2026
